SHL Medical has joined the NSTC Science Train Program for the second consecutive year as part of its human-centered sustainability approach.
SHL and Lifecore will exchange knowledge and experience in their respective fields, enabling both companies to provide their customers unparalleled guidance in CDMO services and best-in-class options for drug delivery device development.
SHL Medical announced the launch of a new webpage for its Molly® Connected Cap autoinjector.
The Alliance Management program will further strengthen SHL Medical’s vertically integrated business model by facilitating customer engagement with other key players within the drug delivery ecosystem.
SHL Medical is excited to announce our participation in the 2023 PFSS Tokyo organized by PDA Japan Chapter on September 12-13 at Sola City Conference Center
SHL Medical is pleased to announce the appointment of Markus Puusepp as Chief Growth Officer (CGO). As CGO, Puusepp will be responsible for accelerating the company’s growth with a focus on innovation and customer experience.
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider. The acquisition is SHL Medical’s response to the growing market demand for drug delivery solutions and will support its manufacturing operations globally, especially the upcoming Swiss manufacturing site in Zug.
SHL will provide its device development expertise, assembly guidance, and production competencies to support the clinical and potential commercial supply of the sonelokimab project.
SHL Medical announced today the release of its Sustainability Report for 2022. The report provides a comprehensive overview of the company’s efforts to promote sustainability and outlines its commitment to a sustainable future.